Right Choice: Ribociclib + Et Vs Combo Chemo In Aggressive Hr+/Her2 Advanced Breast Cancer

RIGHT Choice: ribociclib + ET vs combo chemo in aggressive HR+/HER2− advanced breast cancer

Frontline endocrine therapies and ribociclib in early stage HR+ HER2- breast cancer

SABCS 2022 takeaways

ADAPT trial: Endocrine + ribociclib vs. chemotherapy in HR+/HER2- early breast cancer

Metastatic Hormone Positive Breast Cancer | 2023 KU Breast Cancer Year in Review Conference

Total Health | Oncology

RIBECCA: ribociclib, a CDK4/6 inhibitor in ER+ breast cancer

A correlative analysis of CORALLEEN: preoperative ribociclib +letrozole vs chemo in HR+/HER2- BC

Adding ribociclib to endocrine therapy shows an improvement in invasive DFS in HR+/HER2 BC patients

Hormone Receptor-Positive Advanced Breast Cancer: Challenges and New Treatment Options

ClevelandClinicCME

MONALEESA-2: ribociclib + letrozole in pts with de novo metastatic disease and late recurrence

Safety and efficacy of ribociclib and letrozole in advanced breast cancer – the MONALEESA-2 trial

MONALEESA-3 OS results: fulvestrant/ribociclib in postmenopausal HR+/HER2- advanced breast cancer

Advanced Breast Cancer: Challenges in Pathways Development

Metastatic HER2 Negative Breast Cancer: Emerging Novel Treatment Strategies

Total Health | Oncology

KISQALI® (ribociclib) Mechanism of Action in Metastatic Breast Cancer for Patients

Encouraging Findings With Ribociclib in HR+ Breast Cancer

Targeted Oncology

Remaining questions on the use of frontline CDK4/6 inhibitors + endocrine therapy

Which Metastatic Breast Cancer Treatment Is Right for You? What You Need to Know

Patient Empowerment Network

MAINTAIN: fulvestrant or exemestane +/- ribociclib after anti-estrogen therapy + CDK4/6i in HR+ MBC

Adjuvant Abemaciclib/Ribociclib #monarchE/NATALEE #Best Treatment for Breast cancer #CDK 4/6 -Cure

Cancer education made simple # Chandrakanth MV